Dr. Reddy's Laboratories Limited
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
3455.5% vs price
Base Case (Median)
6160.4% vs price
Bull Case (75th pct.)
7547.6% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-19.56 | -261.5% | High (40%) |
| PE Comparable | $885.72 | 7214.0% | Medium (25%) |
| Graham Number | $630.57 | 5107.0% | Medium (40%) |
| EV/EBITDA | $1000.64 | 8162.9% | Medium (20%) |
| EV/FCF | $363.91 | 2905.0% | Medium (20%) |
| Earnings Power Value | $939.58 | 7658.7% | Medium (50%) |
Based on 6 out of 8 methods, RDY appears undervalued at the current price of $12.11. The base case fair value of $758.14 implies 6160.4% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.